Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|August 24, 2015
The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitorsMarkian M Stec, Kristin L Andrews, Yunxin Bo, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2024
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for FutilityClara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.Acta Gastro-Enterologica Belgica|June 16, 2022
Belgian consensus on irritable bowel syndromeS Kindt, H Louis, H De Schepper, et al.Journal of Medicinal Chemistry|July 1, 2011
Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stabilityMarkian M Stec, Kristin L Andrews, Shon K Booker, et al.Proceedings of the National Academy of Sciences of the United States of America|May 16, 2025
MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screensJan Andersson, Sanne Cowland, Mikkel Vestergaard, et al.Acta Gastro-Enterologica Belgica|June 12, 2025
Belgian consensus on the management of patients with functional dyspepsiaS Kindt, J Arts, P Caenepeel, et al.Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.Molecular Cancer Therapeutics|May 20, 2016
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer ModelsPaul E Hughes, Karen Rex, Sean Caenepeel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung CancerMichael J Giffin, Keegan Cooke, Edward K Lobenhofer, et al.Pageof 12